BI 695501 Versus Humira® in Patients With Active Crohn's Disease: a Randomized, Double-blind, Multicenter, Parallel Group, Exploratory Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms VOLTAIRE-CD
- Sponsors Boehringer Ingelheim
- 18 May 2018 Planned primary completion date changed from 30 Apr 2018 to 28 Mar 2019.
- 30 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Dec 2017 Planned End Date changed from 28 Feb 2019 to 28 Mar 2019.